Related by context. All words. (Click for frequent words.) 79 Previously Treated 78 Patients Treated 78 Monotherapy 78 Prolongs Survival 78 Adjuvant Therapy 77 Is Well Tolerated 77 Improves Survival 77 Combination Treatment 77 Disease Progression 77 Drug Candidate 77 Unfractionated Heparin 76 Protease Inhibitor 76 Meets Primary Endpoint 76 Metastatic Colorectal Cancer 76 Advanced Prostate Cancer 76 Advanced Melanoma 76 Single Dose 76 Cardiovascular Events 76 Rheumatoid Arthritis Patients 76 Survival Benefit 76 Demonstrates Significant 76 Severe Sepsis 76 Diabetic Patients 76 Clinical Trial Results 76 Adjuvant Chemotherapy 76 Well Tolerated 75 Improves Outcomes 75 Low Dose 75 Chronic Hepatitis C 75 Antitumor Activity 75 Treatment Regimen 75 Patients Treated With 75 Previously Untreated 75 Renal Cell Carcinoma 75 Investigational Compound 75 Study Evaluating 75 Advanced Renal Cell 75 Phase III Clinical Trial 75 Phase IIb Trial 75 Phase 2b Clinical Trial 75 Receives Orphan Drug Designation 74 Monoclonal Antibody 74 Patients Receiving 74 Adjuvant Treatment 74 Pooled Analysis 74 Investigational Agent 74 Infected Patients 74 Postmenopausal Women 74 Treating Chronic 74 Anti Tumor 74 Elderly Patients 74 Inhaled Corticosteroids 74 Virus Infection 74 Knee Osteoarthritis 74 Complicated Skin 73 Protease Inhibitors 73 Hepatocellular Carcinoma 73 Anti Tumor Activity 73 Viral Suppression 73 Statistically Significant 73 Phase III Trial 73 Hypertensive Patients 73 Improved Survival 73 Peginterferon 73 Recombinant Human 73 Gene Mutation 73 Epidermal Growth Factor Receptor 73 Versus Placebo 73 Diabetic Neuropathy 73 Statin Therapy 73 Novel Oral 73 Treatment Naive Patients 73 Study Showed 73 Atopic Dermatitis 73 Phase 2b Study 73 Significantly Improved 73 Regimens 73 Advanced Pancreatic Cancer 73 Present Preclinical Data 73 Tumor Growth 73 Appears Safe 73 Metastatic Prostate Cancer 73 Relapsing Multiple Sclerosis 73 Fungal Infections 73 Therapeutic Potential 73 Plus Ribavirin 73 Pediatric Patients 73 Breast Cancer Recurrence 73 Tolerability 73 Presents Preclinical Data 73 Oral Mucositis 73 Trial Evaluating 73 Initiate Clinical Trial 73 Mouse Model 72 Phase 2b Trial 72 Rotavirus Vaccine 72 Oral Fingolimod 72 Pulmonary Arterial Hypertension 72 Orally Active 72 Overactive Bladder 72 Newly Diagnosed Multiple Myeloma 72 Relapsed Refractory 72 Tyrosine Kinase Inhibitor 72 Bosutinib 72 Breast Cancer Patients 72 Anthracycline 72 Factor Receptor 72 Treatment Naïve Patients 72 Autologous Stem Cell Transplantation 72 Skeletal Muscle 72 Shows Efficacy 72 Oral Formulation 72 Brain Metastases 72 Initiates Clinical Trial 72 Efficacious 72 Fixed Dose 72 Controlled Trial 72 Chemoradiation 72 Long Term Efficacy 72 Completes Patient Enrollment 72 Demonstrates Positive 72 Pegylated Interferon 72 Myelodysplastic Syndromes 72 Treated Patients 72 Neoadjuvant Chemotherapy 72 Anticancer Activity 72 Kinase Inhibitor 72 Investigational Drug 72 Demonstrated Significant 72 Chronic Hepatitis B 72 Unresectable 72 Study Demonstrates 72 Capecitabine 72 Vitro Activity 72 Medoxomil 72 Significantly Reduces 72 Hormone Receptor Positive 72 Topical Treatment 72 Phase 2a Clinical Trial 72 Placebo Controlled Trial 72 Nilotinib 72 Invasive Fungal Infections 72 Allergic Rhinitis 72 Hepatitis C Patients 72 Immune Responses 72 Clinical Outcome 72 JAK Inhibitor 72 Lupus Drug 72 Completes Enrollment 72 Meta Analysis 72 Vaccine Candidate 72 Proven Effective 72 Vaccine Adjuvant 72 Prophylactic Treatment 71 Phase IIb Clinical Trial 71 Demonstrates Efficacy 71 Hormone Refractory Prostate Cancer 71 Improve Survival 71 Preclinical Data 71 Demonstrates Potent 71 Interferon Beta 71 Drug Shows Promise 71 Fracture Risk 71 Zoledronic Acid 71 Pivotal Phase III 71 Shows Promise 71 Inhibits 71 Pharmacokinetic Study 71 HCV Protease Inhibitor 71 Clinical Trial Evaluating 71 Peginterferon Alfa 2a 71 Antitumor 71 Non Inferiority 71 Viral Load 71 Pivotal Phase 71 Phase IIa Clinical Trial 71 Lung Cancer Patients 71 Extended Release 71 Demonstrates Potential 71 Patients Undergoing 71 Tiotropium 71 Initiates Clinical Trials 71 Phase III Trials 71 Proves Effective 71 Inflammatory Markers 71 Lung Cancer Trial 71 Colorectal Cancer Patients 71 Hepatitis C Virus 71 Novel Antibiotic 71 Chronic Myeloid Leukemia 71 Lung Cancer Drug 71 First Patient Dosed 71 Interferon Alpha 71 Gastric Cancer 71 Antiviral Activity 71 Epoetin Alfa 71 Adjunctive Therapy 71 FDA Clears 71 Drug Resistant 71 Chronic Sinusitis 71 Patients Suffering 71 Insulin Resistance 71 Kidney Function 71 Clinical Efficacy 71 Metastatic Melanoma 71 Controlled Study 71 Bladder Cancer 71 Aliskiren 71 Polymerase Inhibitor 71 Prostate Cancer Patients 71 FDA Approvals 71 Increased Risk 71 Hospital Acquired Pneumonia 71 Hepatitis C Genotype 71 Shows Promise Against 71 Pivotal Study 71 Combo Therapy 70 Heart Failure Patients 70 Taxane 70 Files IND 70 Small Molecule 70 Cholesterol Lowering Drug 70 Myeloma Patients 70 Receptor Antagonist 70 Malignant Melanoma 70 Significantly Improves 70 Bevacizumab 70 Dendritic Cells 70 Transdermal Patch 70 Subgroup Analysis 70 Tablet Formulation 70 Acute Ischemic Stroke 70 Novel Mechanism 70 Gout Drug 70 Preclinical Study 70 Treatment Experienced 70 Cancer Cells 70 Reduces Risk 70 Therapeutic Antibody 70 NDA Submission 70 Randomized Phase 70 Benign Prostatic Hyperplasia 70 Interferon Alfa 70 Multiple Myeloma Patients 70 Melphalan 70 HER2 Positive Breast Cancer 70 Shows Promising 70 Newly Diagnosed 70 Cardiotoxicity 70 Extended Release Formulation 70 Lenalidomide 70 Pafuramidine 70 Patient Enrollment 70 Effectively Treats 70 Advanced Colorectal Cancer 70 Treatment Naïve 70 Improve Outcomes 70 Osteoporosis Treatment 70 Moxifloxacin 70 Gene Variant 70 Immunotherapeutic 70 Receptor Agonist 70 Achieves Primary Endpoint 70 Drug Combo 70 Dose Escalation 70 Anticoagulant 70 Radical Prostatectomy 70 Hypercholesterolemia 70 Parathyroid Hormone 70 Blood Pressure Drug 70 Prophylaxis 70 Bronchodilator 70 II Clinical Trial 70 Naive Patients 70 Immunosuppressant 70 Plaque Psoriasis 70 Dose Ranging Study 70 Prospective Randomized 70 Investigational Treatment 70 Symptom Relief 70 Nucleoside 70 Fondaparinux 70 Secondary Hyperparathyroidism 70 Venous Thromboembolism 70 Antifungal 70 Teva Provides Update 70 Lung Cancer Survival 70 Bone Metastases 70 Prostate Cancer Vaccine 70 Replacement Therapy 70 Neoadjuvant 70 Hormone Therapy 70 Non Responders 69 Randomized Double Blind 69 Chemotherapeutic Agents 69 Progenitor Cells 69 Efficacy Trial 69 Diabetic Nephropathy 69 Treatment Reduces 69 Submits NDA 69 Fludarabine 69 Confirms Efficacy 69 RNAi Therapeutics 69 Human Monoclonal Antibody 69 Receives Positive Opinion 69 HER2 Positive 69 Mylan Receives Approval 69 RNAi Therapeutic 69 Allogeneic 69 Dasatinib 69 Randomized Clinical Trials 69 Kinase Inhibitors 69 Kidney Transplant Patients 69 Placebo Controlled Study 69 Phase III Pivotal Trial 69 Renal Function 69 IND Application 69 Osteoporosis Drug 69 Treatment Naive HIV 69 FDA Approves 69 Tumor Targeting 69 Systemic Delivery 69 Induces 69 Malaria Vaccine 69 FDA Okays 69 Androgen Deprivation Therapy 69 Commonly Used 69 Novel Compound 69 Pegylated 69 Irinotecan 69 Breast Cancer Cells 69 Epilepsy Drug 69 Subtypes 69 Hepatitis B Virus 69 Data Suggest 69 Interferon Gamma 69 Prodrug 69 Antiviral Drugs 69 Bazedoxifene 69 Fixed Dose Combination 69 Hepatic Encephalopathy 69 Novel Therapeutic 69 Enoxaparin 69 Hemoglobin Levels 69 Cancer Vaccines 69 TB Vaccine 69 Randomized Controlled Trial 69 Erectile Dysfunction Drug 69 Stem Cell Transplants 69 Breast Cancer Treatment 69 Beneficial Effects 69 Experimental Vaccine 69 Tezampanel 69 Signaling Pathway 69 Fluorouracil 69 Localized Prostate Cancer 69 Radiofrequency Ablation 69 Resistant Hypertension 69 Metastatic Breast Cancer 69 Generic Version 69 Insulin Glargine 69 Breast Tumors 69 Estrogen Therapy 69 Sustained Efficacy 69 Ovarian Cancer Patients 69 Pneumococcal Vaccine 69 Cancer Treatments 69 Bosentan 69 Novel Method 69 Double Blind Placebo 69 Predict Risk 69 Antiretroviral Therapy 69 Vaginal Gel 69 Effective Than 69 FDA Accepts 69 Inflammatory Arthritis 69 Phospholipase A2 69 Invasive Breast Cancer 69 Glucose Control 69 Clinical Outcomes 69 Potent Inhibitor 69 Universal Flu Vaccine 69 Immunogenic 69 Rheumatoid Arthritis Drug 69 Metastatic Renal Cell Carcinoma 69 Genes Involved 68 Initiates Phase II 68 Gemcitabine 68 Long Term Outcomes 68 Conjugate 68 Obese Patients 68 Node Positive 68 Chemokine Receptor 68 Cyclooxygenase 2 68 Gene Linked 68 HDAC Inhibitor 68 Relapsing Remitting Multiple Sclerosis 68 ACE Inhibitors 68 Preclinical Models 68 Antiplatelet Therapy 68 Presents Positive 68 Hormonal Therapy 68 Significantly Reduced 68 Initiates Phase III 68 Regenerative Cells 68 Sirolimus Eluting 68 Initiates Clinical 68 Phase 1b Clinical Trial 68 Fewer Side Effects 68 Castration Resistant Prostate Cancer 68 Anticancer Agent 68 Follicular Lymphoma 68 Successfully Treated 68 Targeted Therapies 68 Reduced Risk 68 Adenoma 68 Boceprevir 68 Cardiovascular Outcomes 68 Postmenopausal Osteoporosis 68 Therapeutic Vaccine 68 Molecular Weight Heparin 68 Mycophenolate Mofetil 68 Disease Modifying 68 Systematic Review 68 Adefovir 68 Minimally Invasive Treatment 68 Stem Cell Treatment 68 Anti Inflammatory 68 Severe Asthma 68 Hsp# Inhibitor 68 Lupus Nephritis 68 Vascular Inflammation 68 Aggressive Prostate Cancer 68 Protein Linked 68 Maribavir 68 Breast Cancers 68 Cyclophosphamide 68 Respiratory Virus 68 Carboplatin Paclitaxel 68 Endovascular Treatment 68 Fast Track Status 68 Granted Orphan Drug 68 Novel Inhibitor 68 Contrast Agents 68 Protein Interactions 68 Peginterferon Alfa 2b 68 Confirmatory Phase 68 Aurora Kinase 68 Reduced Incidence 68 Therapeutic Vaccines 68 Platelet Inhibition 68 Pharmacokinetics PK 68 Treatment Naive 68 Soft Tissue Sarcoma 68 Mesalamine 68 Positive Opinion 68 Long Term Survival 68 SPRYCEL ® 68 Bortezomib 68 Inhalation Solution 68 Targeted Therapy 68 Patent Covering 68 Pivotal Trial 68 Cancer Therapies 68 Glatiramer Acetate 68 Montelukast 68 Lowers Risk 68 Arthritis Drug 68 Darbepoetin Alfa 68 Diabetic Foot Ulcers 68 Therapy Improves 68 Immune Cells 68 Serious Infections 68 Expanded Indication 68 Treatment Resistant 68 Advanced Ovarian Cancer 68 Anticancer Drugs 68 Randomized Study 68 Partial Onset Seizures 68 Sustained Virologic Response 68 Cutaneous T 68 Shows Statistically Significant 68 Drug Regimen 68 Antiviral Therapy 68 Cholesterol Drugs 68 Diuretic 68 Bare Metal Stents 68 Oral Insulin 68 Therapeutic Efficacy 68 Trastuzumab 68 Circulating Tumor Cells 68 Posaconazole 68 Anticancer Drug 68 Tumor Cell 68 Inhibitor 68 Decitabine 68 Shown Effective 68 Blood Thinner 68 Randomized Clinical Trial 67 Glufosfamide 67 Oral Spray 67 Cholesterol Levels 67 PRN FDA Approves 67 Therapy Reduces 67 Atypical Antipsychotics 67 Drug Eluting 67 Pivotal Trials 67 See CLINICAL PHARMACOLOGY 67 Nymox NX 67 Prognostic Significance 67 Receives Approvable Letter 67 Cholesterol Drug 67 Phase 2a Trial 67 Liposomal 67 Septic Shock 67 Slow Progression 67 Demonstrates Statistically Significant 67 Osteoporosis Drugs 67 Sustained Release 67 Study Indicates 67 Predict Response 67 Successfully Completes Phase 67 Gene Variants 67 Bivalirudin 67 Tacrolimus 67 Tigecycline 67 PKC# 67 Darunavir 67 Ranolazine 67 Mg Usa 67 Chemotherapy Regimen 67 Diabetic Foot Ulcer 67 Thromboembolism 67 Phase III Clinical Trials 67 Nicotine Vaccine 67 Initiates Phase 67 Receptor Antagonists 67 Enlarged Prostate 67 Randomized Double Blind Placebo 67 Progressive Multifocal Leukoencephalopathy 67 Dose Response 67 Hepatitis B Vaccine 67 Chronic Lymphocytic Leukemia 67 Chronic Heart Failure 67 Refractory Hodgkin Lymphoma 67 Tumor Suppressor 67 Mouse Models 67 Randomized Trials 67 Potent Anti 67 Emerging Therapies 67 Influenza Virus 67 Maleate 67 Erlotinib 67 Pegylated Liposomal Doxorubicin 67 Test Detects 67 Angiogenic 67 Tumor Cells 67 Cardiac Function 67 Sirolimus Eluting Stent 67 Psoriasis Patients 67 Hematological Cancers 67 Epratuzumab 67 Modulates 67 Liver Metastases 67 Generic Versions 67 Genetic Tests 67 Glycemic Control 67 Sevelamer 67 Increases Risk 67 ritonavir boosted 67 Etanercept 67 Blood Pressure Reduction 67 Ecallantide 67 Uric Acid 67 Fulvestrant 67 Myelodysplastic Syndrome MDS 67 Integrase Inhibitor 67 Antidepressant Drug 67 Fluticasone 67 5 Fluorouracil 67 Relapsed Multiple Myeloma 67 Milestone Payment 67 Anti TNF 67 PEGylated Fab fragment 67 Solid Tumors 67 Gastrointestinal Disorders 67 Mucosal 67 Myocardial Ischemia 67 Ziprasidone 67 Oligonucleotides 67 Valsartan 67 Paraplatin ® 67 Schizophrenia Drug 67 Randomized Controlled Trials 67 Vildagliptin 67 Artery Disease 67 Psoriasis Drug 67 Iron Deficiency 67 Protein Synthesis 67 Safinamide 67 Stomach Cancer 67 Malignant Glioma 67 Receives FDA Clearance 67 Corticosteroid 67 Liver Injury 67 Hormone Receptor 67 ST Elevation Myocardial 67 Antibiotic Use 67 Genetic Variation 67 Hemodialysis Patients 67 Migraine Drug 67 Preterm Delivery 67 Effective Treatments 67 Cytotoxicity 67 Acute Coronary Syndromes 67 Oxaliplatin 67 Initiate Phase III 67 Rectal Cancer 67 Receives Milestone Payment 67 Autoimmune Disease 67 Antipsychotic 67 Multidrug Resistance 67 Renal Insufficiency 67 Potent Antiviral Activity 67 Gastric Ulcers 67 FDA Clearance 67 Bone Mineral Density 67 AnaSpec Introduces 67 Hepatitis C Infection 66 Antigen Specific 66 Presents Preclinical 66 Laryngeal Cancer 66 Chemotherapy Improves 66 Platelet Function 66 Inhaled Liposomal Ciprofloxacin 66 Statin Drugs 66 Tumor Progression 66 TNF Blockers 66 Cytotoxic 66 Gum Disease 66 NICE Recommends 66 Tipranavir 66 Clinical Study 66 Left Ventricular 66 Myeloid 66 Valopicitabine 66 Migraine Pain 66 Colorectal Adenomas 66 Blood Vessels 66 leukotriene receptor antagonist 66 Nitazoxanide 66 Renal Cancer 66 Prevent Stroke 66 Prolongs Life 66 Anti Inflammatory Drug 66 Hyperlipidemia 66 Genital Herpes 66 MEK Inhibitor 66 Itraconazole 66 Companion Diagnostic 66 Genes Linked 66 Initiate Phase 66 Asthma Treatment 66 Androgen Receptor 66 Drug Fails 66 Pioglitazone 66 oral prodrug 66 Lymphoid 66 Elagolix 66 Cell Transplants 66 Newly Identified 66 alfa 2b 66 Antiangiogenic 66 Bone Marrow Cells 66 Lanthanum Carbonate 66 Randomized Double blind 66 Adalimumab 66 Suppresses 66 Potentially Fatal 66 Dapagliflozin 66 Leukemias 66 Leucovorin 66 Prostate Cancer Treatment 66 Protease 66 Cyclosporine 66 Tumor Response 66 Phase 2a Study 66 Combination REOLYSIN R 66 Significant Improvement 66 Skin Cancers 66 Immunogenicity 66 Inhalation Aerosol 66 Intravenous Formulation 66 Viral Infection 66 Synthetic Peptide 66 Beta Blockers 66 Cethromycin 66 Renal Impairment 66 Nebulized 66 Combination Vaccine 66 Tyrosine Kinase 66 Combination Therapies 66 Cardiovascular Disease Risk 66 Molecular Diagnostic Test 66 Migraine Treatment 66 Malignancies 66 Recombinant Protein 66 Showed Significant 66 Kidney Transplant Recipients 66 Visceral Fat 66 alfa 2a 66 Liver Failure 66 Adjuvant 66 JAK2 Inhibitor 66 Researchers Identify 66 Osteoarthritis Patients 66 Higher Doses 66 Antiplatelet 66 Autoimmune Diseases 66 Oral Cladribine 66 Pemetrexed 66 gefitinib Iressa 66 Dose Escalation Study 66 RNA Interference 66 Antiretrovirals 66 HCV Genotype 66 5 FU leucovorin 66 Therapy Shows Promise 66 Smooth Muscle 66 Initiates Enrollment 66 Patients Enrolled 66 Renal Tumors 66 Premenopausal Women 66 Treatment Regimens 66 Metabolic Disease 66 Protein Involved 66 Signaling Pathways 66 Early Diagnosis 66 erlotinib Tarceva ® 66 C Reactive Protein 66 Enzyme Replacement Therapy 66 Genes Predict 66 Vaccine Protects Against 66 Thyroid Hormone 66 Omacetaxine 66 Pralatrexate 66 adalimumab Humira 66 Data Indicate 66 STELARA TM 66 Antibacterials 66 Drug Prevents 66 Chemotherapy Induced 66 Develop Novel 66 Primary Hypercholesterolemia 66 Patient Outcomes 66 Multicenter Randomized 66 Bipolar Depression 66 Pertuzumab 66 Infliximab 66 Acute Attacks 66 Denufosol 66 FASLODEX 66 Saquinavir 66 Endometrial Cancer 66 Natalizumab 66 Ozarelix 66 lexidronam injection 66 Viral Infections 66 Calcitonin 66 Ustekinumab 66 Recurrent Breast Cancer 66 von Willebrand Factor 66 Protein Expression 66 Peripheral Blood 66 Endothelial Cells 66 Hepatitis C Virus HCV 66 abacavir sulfate lamivudine 66 IND Filing 66 Golimumab 66 Camptosar ® 66 Based Regimens 66 Adjunctive 66 DNA Methylation 66 Estrogen Receptor 66 Urinary Tract Infections 66 Dual Antiplatelet Therapy 66 Immunomodulatory 66 Testosterone Gel 66 Oncolytic 66 Begins Dosing 66 Immunosuppression 66 Reduces Pain 66 Subunit 66 Reduce Mortality 66 Vitamin D Linked 66 Protein Biomarkers 66 Schizophrenia Treatment 66 Spectrum Pharmaceuticals Announces 66 Metastatic Pancreatic Cancer 65 Budesonide 65 CYP#A# CYP#D# 65 Detect Cancer 65 Tesamorelin 65 Organ Rejection 65 FDA APPROVES 65 Tumor Necrosis Factor 65 Coronary Arteries 65 Neuroprotective Effects 65 Blood Flow 65 Telbivudine 65 Vicriviroc 65 Chronic Inflammation 65 Transcription Factor 65 Disease IBD 65 Gastrointestinal Stromal Tumors 65 Antibody Discovery 65 Double Blind Randomized 65 Beta Blocker 65 Lung Function 65 Hepatitis C Treatment 65 Risk Stratification 65 Inhibitors 65 Dalbavancin 65 Inflammatory Disease 65 Cold Sores 65 Alpha interferons including 65 Ischemic Stroke 65 Cytarabine 65 Combination Clinical Trial 65 Inflammatory Diseases 65 Novel Treatments 65 Percutaneous Tibial Nerve Stimulation 65 Osteoarthritis Pain 65 Cell Proliferation 65 pan HDAC inhibitor 65 Menopausal Women 65 Cognitive Decline 65 Liver Toxicity 65 Zorbtive TM 65 Reports Preclinical Data 65 Physical Function 65 Dose Finding 65 Granulocyte Colony Stimulating Factor 65 Factor Xa Inhibitor 65 Commences Phase 65 Idiopathic Pulmonary Fibrosis 65 Proton Pump Inhibitors 65 Gene Variation 65 Analogs 65 Cypher Sirolimus 65 Dupuytren Contracture 65 Genes Associated 65 Cognitive Function 65 Personalized Immunotherapy 65 Cocaine Addiction 65 Anti CD# Antibody 65 Immunomedics Announces 65 Radiation Dose 65 Clostridium difficile Infection 65 Eluting Stent 65 Improves Quality 65 Antibody Drug Conjugate 65 Anti Angiogenesis 65 Eculizumab 65 Receives Orphan Drug 65 Reduce Risk 65 Intranasal 65 Partial Seizures 65 Therapy Evaluation 65 Seasonal Influenza Vaccine 65 Desvenlafaxine Succinate 65 Smallpox Vaccine 65 Prostate Biopsy 65 Atypical Hemolytic Uremic Syndrome 65 Cerebril TM 65 Blood Pressure Lowering 65 Thrombotic 65 Male Contraceptive 65 Hemorrhagic Stroke 65 Cilostazol 65 sorafenib tablets 65 Sulfonylurea 65 Holds Promise 65 Blood Clotting 65 Aptamer 65 Unstable Angina 65 R lenalidomide 65 Intravesical 65 Clinically Proven 65 Eradicates 65 Initiates Phase 2b 65 Dehydrogenase 65 Analytical Tool 65 Pharmacodynamics 65 Cholesterol Lowering 65 Survival Rates 65 Anemia Drug 65 Premature Infants 65 dasatinib Sprycel ® 65 Develops Novel 65 Less Invasive 65 Bucindolol 65 Attenuates 65 Gemzar ® 65 Adjuvanted 65 Fludara ® 65 Lung Tumors 65 Bisphosphonate 65 PEGylated anti 65 Receives SFDA Approval 65 Randomized Evaluation 65 Oritavancin 65 Blood Clots 65 Antibiotic Treatment 65 Study Evaluates 65 Significant Improvements 65 Relapsed 65 Impairs 65 Salmeterol 65 Initiates Dosing 65 Renal Cell Cancer 65 Phase Ib Clinical Trial 65 FDA Approves Drug 65 Clopidogrel 65 Oral Contraceptive 65 TNF Tumor Necrosis Factor 65 Slows Progression 65 complement inhibitor eculizumab 65 Lung Cancers 65 Polymorphisms 65 Binding Protein 65 Bacterial Infections 65 Induction Therapy 65 Lung Injury 65 Juvenile Idiopathic Arthritis 65 Occlusive Disease 65 investigational oral inhibitor 65 Asthma Symptoms 65 Anticancer Compound 65 Breast Cancer Risk 65 Begin Clinical Trials 65 Leukemia Cells 65 Prove Effective 65 Squamous Cell Carcinoma 65 uricase 65 Renal Anemia 65 Human Antibody 65 Lipid Lowering 65 Commercialize Novel 65 Menopausal Symptoms 65 Complete Remission 65 Randomised Controlled Trial 65 Mg Uk 65 Basal Insulin 65 Levels Linked 65 Radioimmunotherapy 65 Venous Thrombosis 65 Obesity Linked 65 Oral Cavity 65 Phase III Pivotal 65 FDA Approval 65 Severe Acne 65 Transdermal Delivery 65 Lung Cancer Risk 65 Insulin Sensitivity 65 dasatinib Sprycel 65 Entry Inhibitor 65 Dengue Virus 65 TNF Alpha 65 CCX# B 65 Cardiomyocytes 65 Ischemic 65 Demonstrates Sustained 65 Loading Dose 65 Cell Lung Cancer 65 Cerebrospinal Fluid 65 dual endothelin receptor antagonist 65 Cell Adhesion 65 Randomized Phase II 64 Stakeholder Opinions 64 Sipuleucel T 64 Myelofibrosis 64 Placebo Controlled 64 Brain Atrophy 64 Lipid Levels 64 Drug Resistant TB 64 Acute Heart Failure 64 Non Alcoholic Fatty 64 Preclinical Efficacy 64 Gram Positive 64 J Am Coll 64 humanized monoclonal 64 Colorectal Cancer Risk 64 Proteasome 64 Retinal Vein Occlusion 64 Stent Implantation 64 Allergic Asthma 64 Telaprevir VX 64 Temsirolimus